Biogen Inc.
- BID
174.06
- ASK
175.8
- 188 Units185 Units
- 07/21, 12:53:26 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
63.15%
Market Cap
25.87 Bil.
P/E Ratio
20.02
Dividend Yield
0.00 %
Earnings per Share
7.79 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE | 174.04 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 12:51:29 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 174.38 | 173.86 |
| PREV. DAY'S PRICE | 175.22 | (07/20) |
| CHANGE DAY BEFORE | -1.18 | -0.67 % |
| 52 WEEK HIGH / LOW | 190.98 (06/30) | 104.2 (07/21) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 7.38 | 10.34 | 7.79 | 12.03 | 14.38 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | 32.45 | 13.67 | 20.02 | 14.97 | 12.52 |
PRICE - BOOK RATIO | 2.53 | 1.33 | 1.42 | - | - |
PRICE - SALES RATIO | 4.00 | 2.41 | 2.72 | - | - |
PRICE - CASH FLOW RATIO | 24.35 | 7.76 | 11.74 | - | - |
Master Data
| WKN | 789617 |
| ISIN | US09062X1037 |
| SYMBOL | IDP |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Biogen Idec |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 147.64 Mil. |
| MARKET CAPITALISATION | 25.87 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -4.56 % | 2.68 % | 12.86 % | 24.27 % | 63.15 % | -28.60 % | -35.76 % | 16.74 % |
| HIGH | 184.78 | 190.98 | 190.98 | 190.98 | 190.98 | 253.00 | 318.45 | 190.98 |
| LOW | 164.76 | 164.76 | 152.72 | 139.45 | 104.20 | 99.06 | 99.06 | 135.15 |
Dividende
pro Aktie
Biogen Idec does not deliver dividend information
Company profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Structured products for Biogen Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.